Filtered By:
Source: Diabetes, Obesity and Metabolism
Condition: Heart Attack

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 60 results found since Jan 2013.

Case–control study of second‐line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke
ABSTRACT We conducted a population‐based case–control study to assess the myocardial infarction (MI) and stroke risks associated with sulfonylureas and insulin when used in combination with metformin. Cases had type 2 diabetes and used metformin + insulin or metformin + sulfonylureas at the time of a first MI or first stroke from 1995–2010; controls used the same treatment combinations and were randomly sampled from the same population. MI and stroke diagnoses and potential confounders were validated by medical record reviews. Compared with metformin + sulfonylurea, metformin + insulin was associated ...
Source: Diabetes, Obesity and Metabolism - July 14, 2015 Category: Endocrinology Authors: James S. Floyd, Kerri L. Wiggins, Colleen M. Sitlani, James H. Flory, Sascha Dublin, Nicholas L. Smith, Susan R. Heckbert, Bruce M. Psaty Tags: Research Letter Source Type: research

Association of Glucagon ‐like Peptide‐1 Receptor Agonist (GLP‐1 RA) Use and Rates of Acute Myocardial Infarction, Stroke, and Overall Mortality in Patients with Type 2 Diabetes Mellitus in a Large Integrated Health System
ConclusionsGLP‐1 RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
Source: Diabetes, Obesity and Metabolism - April 13, 2017 Category: Endocrinology Authors: Robert S. Zimmerman, Todd M. Hobbs, Brian J. Wells, Sheldon X. Kong, Michael W. Kattan, Jon Bouchard, Kevin M. Chagin, Changhong Yu, Brian Sakurada, Alex Milinovich, Wayne Weng, Janine M. Bauman, Kevin M. Pantalone Tags: ORIGINAL ARTICLE Source Type: research

Association of glucagon ‐like peptide‐1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system
Conclusions GLP‐1RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
Source: Diabetes, Obesity and Metabolism - July 5, 2017 Category: Endocrinology Authors: Robert S. Zimmerman, Todd M. Hobbs, Brian J. Wells, Sheldon X. Kong, Michael W. Kattan, Jon Bouchard, Kevin M. Chagin, Changhong Yu, Brian Sakurada, Alex Milinovich, Wayne Weng, Janine M. Bauman, Kevin M. Pantalone Tags: ORIGINAL ARTICLE Source Type: research

No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase 4 inhibitors versus therapeutic alternatives
ConclusionThough limited by the short treatment duration, our study suggests no increased short‐term risk of MI stroke or HF with DPP‐4i versus SU/TZD.
Source: Diabetes, Obesity and Metabolism - January 31, 2017 Category: Endocrinology Authors: Mugdha Gokhale, John B. Buse, Michele Jonsson Funk, Jennifer Lund, Virginia Pate, Ross J Simpson, Til St ürmer Tags: ORIGINAL ARTICLE Source Type: research

No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase ‐4 inhibitors vs therapeutic alternatives
ConclusionAlthough limited by the short treatment period, the present study suggests there is no increased short‐term risk of MI, stroke or HF with DPP‐4 inhibitors vs SUs/TZDs.
Source: Diabetes, Obesity and Metabolism - March 16, 2017 Category: Endocrinology Authors: Mugdha Gokhale, John B. Buse, Michele Jonsson Funk, Jennifer Lund, Virginia Pate, Ross J. Simpson, Til St ürmer Tags: ORIGINAL ARTICLE Source Type: research

Plasma PCSK9 and Cardiovascular Events in Type 2 Diabetes
ConclusionsPCSK9 is inconsistently associated with CV events in populations with T2DM. The association may depend on the level of CV risk and the background treatment
Source: Diabetes, Obesity and Metabolism - December 5, 2017 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, P. Gabriel Steg, Louis Potier, Youmna Ghaleb, S El Bitar, S Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Hadjadj, Catheri Tags: ORIGINAL ARTICLE Source Type: research

Plasma proprotein ‐convertase‐subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
ConclusionsWe found that PCSK9 was inconsistently associated with CV events in populations with type 2 diabetes. The association may depend on the level of CV risk and the background treatment.
Source: Diabetes, Obesity and Metabolism - January 14, 2018 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, Philippe Gabriel Steg, Louis Potier, Youmna Ghaleb, Sandy Elbitar, Stephanie Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Tags: ORIGINAL ARTICLE Source Type: research

Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor
ABSTRACT The recently completed EMPA‐REG study demonstrated that empagliflozin significantly decreased the MACE endpoint (cardiovascular death, nonfatal MI, stroke) in high risk type 2 diabetic patients, primarily due to a reduction in cardiovascular death, without a significant decrease in either myocardial infarction or stroke. In PROactive, pioglitazone decreased the MACE endpoint by a similar degree to that in EMPA‐REG, due to a marked reduction in both recurrent myocardial infarction and stroke and a modest reduction in cardiovascular death. These observations suggest that pioglitazone might be an ideal agent to c...
Source: Diabetes, Obesity and Metabolism - February 25, 2016 Category: Endocrinology Authors: Ralph A. DeFronzo, Robert Chilton, Luke Norton, Geoffrey Clarke, Robert E.J. Ryder, Muhammad Abdul‐Ghani Tags: ORIGINAL ARTICLE Source Type: research

Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor
The recently completed EMPA‐REG study showed that empagliflozin significantly decreased the major adverse cardiac events (MACE) endpoint, which comprised cardiovascular death, non‐fatal myocardial infarction (MI) and stroke, in patients with high‐risk type 2 diabetes (T2DM), primarily through a reduction in cardiovascular death, without a significant decrease in either MI or stroke. In the PROactive study, pioglitazone decreased the MACE endpoint by a similar degree to that observed in the EMPA‐REG study, through a marked reduction in both recurrent MI and stroke and a modest reduction in cardiovascular death. Thes...
Source: Diabetes, Obesity and Metabolism - April 5, 2016 Category: Endocrinology Authors: R. A. DeFronzo, R. Chilton, L. Norton, G. Clarke, R. E. J. Ryder, M. Abdul‐Ghani Tags: PERSPECTIVE Source Type: research

Cardiovascular Safety Of Sulfonylureas: A Meta‐Analysis Of Randomised Clinical Trials
ConclusionsIn type 2 diabetes, the use of sulfonylureas is associated with increased mortality and a higher risk of stroke, whereas the overall incidence of MACE appears to be unaffected. Significant differences in cardiovascular risk could be present in direct comparisons with specific classes of glucose‐lowering agents, such as DPP4 inhibitors, but this hypothesis needs to be confirmed in long‐term cardiovascular outcomes trials. The results of this meta‐analysis need to be interpreted with caution, mainly because of limitations in trial quality and under‐reporting of information on cardiovascular events and mort...
Source: Diabetes, Obesity and Metabolism - April 22, 2013 Category: Endocrinology Authors: Matteo Monami, Stefano Genovese, Edoardo Mannucci Tags: Original Paper Source Type: research

Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials
ConclusionsIn type 2 diabetes, the use of sulfonylureas is associated with increased mortality and a higher risk of stroke, whereas the overall incidence of MACE appears to be unaffected. Significant differences in cardiovascular risk could be present in direct comparisons with specific classes of glucose‐lowering agents, such as DPP4 inhibitors, but this hypothesis needs to be confirmed in long‐term cardiovascular outcomes trials. The results of this meta‐analysis need to be interpreted with caution, mainly because of limitations in trial quality and under‐reporting of information on cardiovascular events and mort...
Source: Diabetes, Obesity and Metabolism - May 13, 2013 Category: Endocrinology Authors: M. Monami, S. Genovese, E. Mannucci Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular safety of combination therapies with incretin based drugs and metformin compared with a combination of metformin and sulfonylurea in type 2 diabetes mellitus – a retrospective nationwide study
ConclusionIncretin‐based drugs combined with metformin were safe compared with conventional combinations of glucose‐lowering therapy. Use of incretin‐based therapy may be target for strategies to lower cardiovascular risk in type‐2 diabetes, although it should be recognized that the multivariable analysis may not have fully accounted for important baseline differences.
Source: Diabetes, Obesity and Metabolism - May 14, 2014 Category: Endocrinology Authors: Ulrik Madvig Mogensen, Charlotte Andersson, Emil Loldrup Fosbøl, Tina Ken Schramm, Allan Vaag, Nikolai Madrid Scheller, Christian Torp‐Pedersen, Gunnar Gislason, Lars Køber Tags: ORIGINAL PAPER Source Type: research

Cardiovascular safety of combination therapies with incretin‐based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus – a retrospective nationwide study
ConclusionIncretin‐based drugs combined with metformin were safe compared with conventional combinations of glucose‐lowering therapy. Use of incretin‐based therapy may be target for strategies to lower CV risk in type 2 diabetes, although it should be recognized that the multivariable analysis may not have fully accounted for important baseline differences.
Source: Diabetes, Obesity and Metabolism - June 9, 2014 Category: Endocrinology Authors: U. M. Mogensen, C. Andersson, E. L. Fosbøl, T. K. Schramm, A. Vaag, N. M. Scheller, C. Torp‐Pedersen, G. Gislason, L. Køber Tags: ORIGINAL ARTICLE Source Type: research

Regional, age, and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ConclusionCV risk factors of TECOS participants are reasonably controlled on average, but differences in CV risk management according to region, sex, and history of prior disease exist. This diversity will enhance generalizability of the trial results.
Source: Diabetes, Obesity and Metabolism - January 20, 2015 Category: Endocrinology Authors: M. A. Bethel, J.B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, Tags: ORIGINAL ARTICLE Source Type: research

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ConclusionThe CV risk factors of participants in TECOS are reasonably controlled, but differences in CV risk management according to region, sex and history of disease exist. This diversity will enhance the generalizability of the trial results.
Source: Diabetes, Obesity and Metabolism - February 13, 2015 Category: Endocrinology Authors: M. A. Bethel, J. B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, Tags: ORIGINAL ARTICLE Source Type: research